

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

0075470.020201





Fig. 1

APPROVED	O.G. FIG.	
By	CLASS	SUBCLASS
DRAFTSMAN		

FOUO 6454260




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

WO 98/23299


PCT/CA97/00892

3/9


Oligonucleotide synthesized in 2 parts




Label 5' end of one sequence



Anneal both parts to complementary sequence



Ligate the 2 parts of the oligonucleotide



Separate the 2 strands and purify the oligonucleotide





FIG. 3

^{32}P labelled oligonucleotide stability

Incubation period with SMC (d)

0 1 2 3 4 5 6 7



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FOUO 6415460




Fig. 5

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

102020-6245460





Fig. 6

APPROVED	Q.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

09775479.020201




Fig. 8

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

0975479.020201




Fig. 9

102020" 64h5460

Figure 1: Effect of 32P internally labeled oligonucleotides on smooth muscle cells proliferation




Fig. 10

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

102020" 6415460




Fig. 11

APPROVED	O. G. FIG.	
BY	GLASS	SUBCLASS
DRAFTSMAN	•	

FO2020" 64434460



Fig. 12A




Fig. 12B




Fig. 12C

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Control injured
 Oliglow injured




Fig. 13